New monthly shot could tame rare kidney disease
NCT ID NCT07020923
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called atacicept given once a month to people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if monthly dosing lowers harmful antibodies and reduces protein in the urine, which are signs of kidney damage. About 90 adults are taking part in this Phase 2 trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- atacicept
- What this could lead to
- If successful, this could lead to a more convenient monthly dosing option for controlling IgA nephropathy, potentially slowing kidney damage.
- What could go wrong
- This is an early Phase 2 study with only 90 participants, so results may not confirm effectiveness or safety. The drug may not reduce protein in urine enough to benefit patients long-term.
Why investors are watching
Vera Therapeutics is testing atacicept in patients with IgAN, a kidney disease, in a Phase 2 trial with 90 participants. The trial compares monthly dosing against weekly dosing, which matters because a monthly option could make the drug more convenient and competitive. For a small company like Vera, this readout is a key test of whether atacicept can support a broader commercial case.
If it works: A positive result could show that monthly dosing works as well as weekly, giving Vera a stronger product profile. That could help the company advance atacicept toward later-stage development and a potential market entry.
If it fails: The trial could fail to show that monthly dosing is effective, or the results could be mixed. Trials often fail, and for a small company, a disappointing readout could set back the drug's development and put pressure on the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study assessments * Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments * Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years * Total urine protein excretion ≥0.75 g per 24-hour or urine protein-to-creatinine ratio (UPCR) ≥0.75 mg/mg based on a 24-hour urine sample * eGFR ≥30 mL/min/1.73 m2 at screening, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) * On a stable prescribed regimen of RASi (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker) for at least 8 weeks that is at the maximum labeled or tolerated dose at screening and from screening to study Day 1 Exclusion Criteria: * IgAN secondary to another condition (eg, liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (ie, Henoch-Schonlein purpura), systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis * Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months of screening) * Evidence of nephrotic syndrome within 6 months of screening (serum albumin \<3.0 g/dL in association with UPCR \>3.5 mg/mg) * Renal or other organ transplantation prior to or expected during the study, with the exception of corneal transplants * Concomitant chronic renal disease in addition to IgAN (eg, diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, C3 glomerulopathy, lupus nephritis)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Berger disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vera Therapeutics
Brisbane, California, 94005, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may help doctors Fine-Tune kidney disease therapy
- Can a daily pill protect kidneys in IgA nephropathy? MRI study puts atrasentan to the test
- Can AI learn to spot kidney disease in biopsy images?
- Can a single injection drug calm the immune attack on kidneys?
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test